Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,580.70 +125.86 1.01%
S&P 500 1,332.42 +14.60 1.11%
Nasdaq 2,870.99 +33.46 1.18%
Ticker Volume Price Price Delta
STOXX 50 2,160.31 +12.39 0.58%
FTSE 100 5,391.14 +34.80 0.65%
DAX 6,396.84 +73.65 1.16%
Ticker Volume Price Price Delta
Nikkei 8,587.74 -69.34 -0.80%
TOPIX 720.74 -6.29 -0.87%
Hang Seng 18,696.80 -358.66 -1.88%
Gold 1,549.00 -0.13%
EUR-USD 1.2471 -0.2537%
Nasdaq 2,870.99 +1.18%
DJIA 12,580.70 +1.01%
S&P 500 1,332.42 +1.11%
FTSE 100 5,391.14 +0.65%
STOXX 50 2,160.31 +0.58%
DAX 6,396.84 +1.16%
Oil (WTI) 90.38 -0.42%
U.S. 10-year 1.719% -0.026
BAC:US 7.44 +4.06%
FB:US 28.84 -9.62%
  • Exchange: NASDAQ CM
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Therapeutics

Threshold Pharmaceuticals Inc

Add to Portfolio

THLD:US

6.9400 USD 0.1400 2.06%

As of 20:10:00 ET on 05/29/2012.

Snapshot for Threshold Pharmaceuticals Inc (THLD)

Open: 6.8100 Day's Range: 6.8100 - 7.1000 Volume: 1,263,825 Bid: 6.9400
Previous Close: 6.8000 52wk Range: 1.1800 - 9.0700 1-Yr Rtn: +305.85% Ask: 6.9500

Stock Chart for THLD

No chart data available.
  • THLD:US 6.9400
  • 1D
  • 1M
  • 1Y
6.8000
Interactive THLD Chart

Previous Close

Key Statistics for THLD

Current P/E Ratio (ttm) -
Estimated P/E (12/2012) -
Earnings Per Share (USD) (ttm) -2.6500
Est. EPS (USD) (12/2012) -2.4030
Est. PEG Ratio -
Market Cap (M USD) 378.23
Shares Outstanding (M) 54.50
Enterprise Value (M USD) (ttm) 328.50
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) -
Price/Sale (ttm) 1,106.9708
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 08/03/2012
More THLD Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for THLD

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)
More THLD Income Statement Data
  • Total Assets
  • Total Liabilities (M/USD)
  • Debt to Assets (%)
More THLD Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/USD)
More THLD Cash Flow Data

Company Profile & Key Executives for THLD

Threshold Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development and commercialization of small molecule therapeutics based on Metabolic Targeting, an approach that targets fundamental differences in metabolism between normal and certain diseased cells.

Harold E Selick "Barry"Chief Executive OfficerTillman PearceChief Medical Officer
Mark G MatteucciSenior VP:Discovery ResearchRobert L Simon "Bob"Senior VP:Regulatory Affairs
More Company Profile & Key Executives for THLD

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements